Aclaris Q3 net loss widens to $21.1M; cash $243.6M; IND filed for ATI-2138

Aclaris Therapeutics, Inc.

2022-Q3 EPS reported -$1.23 revenue$5,260,000

Net loss Q3 2021: $21.1M vs $10.7M in Q3 2020; revenue $1.7M vs $1.4M.
Cash, cash equivalents and marketable securities of $243.6M as of Sep 30, 2021; runway through end of 2024.
IND submitted in Oct 2021 for ATI-2138, an oral ITK/TXK/JAK3 inhibitor for psoriasis.
Zunsemetinib (ATI-450) Phase 2b in RA planned Q4 2021; Phase 2 trials in psoriatic arthritis and hidradenitis suppurativa planned.
Kamil Ali-Jackson, Chief Legal Officer and Co-Founder, retiring effective Jan 3, 2022; severance includes salary, bonus, vesting acceleration.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kamil Ali-Jackson

Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary

ACRS · Aclaris Therapeutics, Inc.

Effective: 2022-01-03
Filed: November 2, 2021, 7:59 PM ET

On November 1, 2021, Ms. Ali-Jackson notified the Company that she will retire from her position as the Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of the Company, effective January 3, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kamil Ali-Jackson retired as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary at Aclaris Therapeutics, Inc..

Action: retired
Role: Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary

Exact text from the filing

On November 1, 2021, Ms. Ali-Jackson notified the Company that she will retire from her position as the Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of the Company, effective January 3, 2022

View on SEC.gov

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-21-013985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.